Core Insights - Mirxes has been awarded the "Sunshine" Award for its innovative non-invasive early screening technology, GASTROClear™, which has been recognized for its significant clinical value in the field of gastric cancer early detection [1][3]. Group 1: Award and Recognition - The "Sunshine" Award is part of the 21st Century Health Industry Competitiveness Research, which aims to promote high-quality development in the health industry and support the "Healthy China" strategy [3]. - GASTROClear™ is the first non-invasive gastric cancer screening product in China to receive NMPA Class III medical device registration, marking a significant advancement in the field [4][5]. Group 2: Clinical and Market Impact - GASTROClear™ utilizes a proprietary miRNA technology platform to detect 12 types of microRNAs in human serum, achieving a sensitivity of 85% and a negative predictive value of 99.4%, thus effectively identifying high-risk gastric cancer patients [4]. - Gastric cancer is a major health issue in China, accounting for 43% of new global cases, with a current early diagnosis rate of less than 20% [5]. Group 3: Strategic Collaborations and Future Developments - Mirxes has entered into strategic partnerships with Watson Bio and Crystal Technology to enhance its capabilities in molecular diagnostics and AI-driven solutions for early cancer detection and intervention [6][7]. - The company aims to build an integrated ecosystem from diagnosis to treatment, leveraging its technological innovations and strategic collaborations to expand its market presence globally [7].

Core Viewpoint - Mirxes Holding Company Limited has received NMPA approval for its non-invasive gastric cancer early screening product, GASTROClear™, marking a significant advancement in early detection methods for gastric cancer in China [1][2]. Group 1: Product Approval and Market Potential - GASTROClear™ is the first non-invasive diagnostic product for gastric cancer screening in China, filling a critical gap in the market [1][2]. - The product targets high-risk populations defined by specific criteria, with an estimated screening population exceeding 500 million, indicating substantial demand for early detection [2]. - The global gastric cancer screening market has grown from $13 billion in 2019 to $15.2 billion in 2023, with projections to exceed $25 billion by 2033, highlighting significant market potential [4]. Group 2: Clinical Research and Technology - The approval of GASTROClear™ is based on a rigorous clinical trial involving approximately 10,000 participants, making it one of the largest prospective studies in the field of gastric cancer molecular detection [2][6]. - The product utilizes a proprietary miRNA technology that offers early detection capabilities, stability, and non-invasive testing, addressing traditional challenges in cancer screening [5][7]. Group 3: Clinical Positioning and Public Health Impact - GASTROClear™ is positioned as a preventive tool for asymptomatic high-risk individuals, differentiating it from auxiliary diagnostic products that assist in confirming existing symptoms [9]. - The product's high sensitivity complements existing serological screening methods and forms an effective system with endoscopic examinations, enhancing early detection rates and reducing costs [10]. - The introduction of GASTROClear™ supports the goals outlined in the "Healthy China 2030" initiative, aiming to improve cancer prevention and control strategies [10].